PFKFB3-dependent redox homeostasis and DNA repair support cell survival under EGFR-TKIs in non-small cell lung carcinoma

PFKFB3-dependent redox homeostasis and DNA repair support cell survival under EGFR-TKIs in non-small cell lung carcinoma

Abstract Background The efficacy of tyrosine kinase inhibitors (TKIs) targeting the EGFR is limited due to the persistence of drug-tolerant cell populations, leading to therapy resistance. Non-genetic mechanisms, such as metabolic rewiring, play a significant role in driving lung cancer cells into t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nadiia Lypova, Susan M. Dougherty, Brian F. Clem, Jing Feng, Xinmin Yin, Xiang Zhang, Xiaohong Li, Jason A. Chesney, Yoannis Imbert-Fernandez
Format:	Article
Language:	English
Published:	BMC 2024-12-01
Series:	Cancer & Metabolism
Subjects:	Non-small cell lung carcinoma EGFR PFKFB3 GPX4 Oxidative stress Base excision DNA repair
Online Access:	https://doi.org/10.1186/s40170-024-00366-y
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

MicroRNA‐488 inhibits proliferation and glycolysis in human prostate cancer cells by regulating PFKFB3
by: Jun Wang, et al.
Published: (2019-10-01)

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
by: Yinan Xiao, et al.
Published: (2025-01-01)

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer
by: Koh Furugaki, et al.
Published: (2025-02-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
by: Hua-Jun Chen, et al.
Published: (2025-01-01)

A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified  Lung Squamous Cell Carcinoma and Literature Review
by: Yalan LIU, et al.
Published: (2024-11-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis
by: Mingfeng He, et al.
Published: (2025-01-01)

Evaluation of EGFR-TKIs and ICIs treatment stratification in non-small cell lung cancer using an encrypted multidimensional radiomics approach
by: Xingping Zhang, et al.
Published: (2025-01-01)

Non-small Cell Lung Cancer Cell Line PC-9 Drug-resistant Mutant Cell Line  Establishment and Validation of Their Sensitivity to EGFR Inhibitors
by: Tao HU, et al.
Published: (2024-11-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

EGFR as a biomarker of smoking status and survival in oropharyngeal squamous cell carcinoma
by: Shanmugappiriya Sivarajah, et al.
Published: (2019-01-01)

Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2025-01-01)

OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway
by: Zehang Zheng, et al.
Published: (2024-12-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Toxic effects of polystyrene nanoplastics on MDA-MB-231 breast cancer and HFF-2 normal fibroblast cells: viability, cell death, cell cycle and antioxidant enzyme activity
by: Hanie Sadeghinia, et al.
Published: (2025-01-01)

Study of the association of the known prognostic variables with EGFR expression in head and neck squamous cell carcinomas
by: Toyaja Jadhav, et al.
Published: (2023-07-01)

Determination of lipid peroxidation biomarkers in vero cell line inoculated with bovine ephemeral fever virus
by: Oguzhan Avci*, et al.

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling
by: Xindong Wei, et al.
Published: (2025-01-01)

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer
by: Yuhong Ma, et al.
Published: (2024-12-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Inhibition of glutathione peroxidase 4 suppresses gastric cancer peritoneal metastasis via regulation of RCC2 homeostasis
by: Can Hu, et al.
Published: (2025-03-01)

The Electric Field Guided HaCaT Cell Migration Through the EGFR/p38 MAPK/Akt Pathway
by: Huajian Zhou, et al.
Published: (2024-12-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells
by: Fumiya Ito, et al.
Published: (2025-01-01)

Bleomycin pollution and lung health: The therapeutic potential of peimine in bleomycin-induced pulmonary fibrosis by inhibiting glycolysis
by: Kangchen Li, et al.
Published: (2025-01-01)

Design, synthesis, and apoptotic antiproliferative action of new benzimidazole/1,2,3-triazole hybrids as EGFR inhibitors
by: Alshimaa A. Y. Ahmed, et al.
Published: (2025-01-01)

Baicalein inhibits PRRSV through direct binding, targeting EGFR, and enhancing immune response
by: Jing Wu, et al.
Published: (2025-01-01)

EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer
by: Huilin Cui, et al.
Published: (2024-11-01)

Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer
by: Wentao Tian, et al.
Published: (2024-08-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)

Nuclear epidermal growth factor receptor (nEGFR) in clinical treatment
by: Junkan Zhu, et al.
Published: (2024-11-01)

Responsive afatinib treatment in high-grade salivary gland ductal carcinoma and NSCLC with uncommon EGFR mutations: Treatment outcomes
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

Expression of EGFR family and p53 in a patient with Synchronous Primary Endometrial Adenocarcinoma and Clear Cell Renal Carcinoma: a Case Report
by: Priscila Fernanda da Silva Martins, et al.
Published: (2019-01-01)

Gasdermin D regulates the activation of EGFR in colorectal cancer
by: Ying Li, et al.
Published: (2024-12-01)